<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172351</url>
  </required_header>
  <id_info>
    <org_study_id>AT LARA 829MP BER-401-16</org_study_id>
    <nct_id>NCT03172351</nct_id>
  </id_info>
  <brief_title>EDoF IOLs vs Monofocal IOL</brief_title>
  <official_title>Prospective Randomized Clinical Trial Comparing Extended Depth of Focus Intraocular Lenses With a Monofocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      prospective, comparative (3 arms), randomized, multicentric clinical trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Defocus curve measurement</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>EDoF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monofocal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDoF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EDoF1</intervention_name>
    <description>extended depth of focus IOL - EDoF1</description>
    <arm_group_label>EDoF2</arm_group_label>
    <arm_group_label>Monofocal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monofocal</intervention_name>
    <description>Monofocal IOL</description>
    <arm_group_label>EDoF1</arm_group_label>
    <arm_group_label>EDoF2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EDoF2</intervention_name>
    <description>Comparison EDoF2 IOL</description>
    <arm_group_label>EDoF1</arm_group_label>
    <arm_group_label>Monofocal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient informed of the consequences and constraints of the Clinical Investigational
             Plan and who has given his/her written informed consent;

          -  Patients of any gender, aged 50 to 80 years;

          -  Assured follow-up examinations;

          -  clinically significant bilateral cataract;

        Exclusion Criteria:

          -  Patients unable to meet the limitations of the Clinical Investigational Plan or likely
             of non-cooperation during the trial;

          -  Patients whose freedom is impaired by administrative or legal order;

          -  Current participation in another drug or device investigation;

          -  Ocular disorders, other than cataract, that could potentially cause future acuity loss
             to a level of 0.20 logMAR (corrected) or worse in either eye

          -  Any anterior segment pathology that could significantly affect outcomes (e.g. chronic
             uveitis, iritis, corneal dystrophy, etc.)

          -  Pseudoexfoliations syndrome

          -  Pathologic miosis or Pharmacotherapy with miotic agent

          -  Keratoconus

          -  Chronic or recurrent uveitis

          -  Diabetic retinopathy

          -  Uncontrolled glaucoma and or IOP&gt;24mmHg

          -  Choroidal hemorrhage,

          -  All kind of infections (acute ocular disease, external/internal infection, systemic
             infection)

          -  Traumatic cataract

          -  Aniridia

          -  Microphthalmia

          -  Amblyopia

          -  Degenerative visual disorders (e.g. macular degeneration, optic nerve atrophy, or
             retinal disorders)

          -  Patient expected to require retinal laser treatment before the end of the 4-6 months
             follow-up

          -  Previous intraocular and corneal surgery

          -  Expected postop. astigmatism greater than 1 D

          -  Any type of corneal disorder

          -  Systemic or ocular pharmacotherapy, which can impact the visual acuity,

          -  Former, current or foreseeable application of Tamsulosin or Silodosin (e.g. Flomax,
             Flomaxtra, Rapflo) ) which potentially can cause the floppy iris syndrome,
             insufficient dilation, or missing of appropriate iris structures which can compromise
             the standard procedure according to the investigator's opinion

          -  Patients who are unable to fixate for longer time (e.g. strabismus, nystagmus)

          -  Dementia

          -  pregnancy or lactation period for female patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zeiss Study Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

